A clinical trial studying tirzepatide in obesity-driven endometrial cancer was listed as recruiting on September 11, 2026. The study, titled "Tirzepatide in Obesity-Driven Endometrial Cancer," is registered under identifier NCT07065552. It is classified as an early phase 1 trial, indicating an initial stage of clinical investigation. Tirzepatide, an approved compound, is being examined in this new trial context involving patients with obesity-driven endometrial cancer.
The trial status is currently listed as recruiting, meaning the study is open to enrolling participants as of the date reported. No outcomes, efficacy data, or safety results have been reported for this trial at this stage. The registration reflects only the trial's design and current recruitment status, not any findings.
Details of the trial, including its full protocol and eligibility criteria, are available through the official clinical trial registry listing. As with any early phase study, the recruiting status indicates the trial is in its early stages, with no results yet available.
Readers interested in tirzepatide's broader development history and regulatory background can consult the compound overview for additional context.